Oestrogen, HRT and Bone Density Explained

What does oestrogen actually do to your bones?

Oestrogen is one of the most important regulators of bone strength in a woman's body — it keeps the constant cycle of bone breakdown and rebuilding in balance. Bone is living tissue that is continually broken down by cells called osteoclasts and rebuilt by osteoblasts. Oestrogen restrains the breakdown side of that cycle. When oestrogen is plentiful, bone is renewed at roughly the rate it is removed.

At menopause, the ovaries stop producing oestrogen and levels fall sharply. With that brake released, bone is broken down faster than it is replaced, and bone density declines. As the NHS puts it, osteoporosis "is common after the menopause because your level of oestrogen falls" — and the same source describes osteoporosis as a thinning of the bones that makes a fracture more likely (NHS, HRT benefits and risks). This is the mechanism behind every other point in this article: replace the oestrogen, and you restore some of that protective brake.

How much bone do women lose after menopause — and how quickly?

The honest answer is that the rate varies a great deal between women — but the pattern is consistent: bone loss accelerates around menopause and is fastest in the first years after periods stop. Once oestrogen falls, the balance tips towards bone removal, and density drops more quickly than the slow, steady loss seen with normal ageing before menopause.

Because this early phase of faster loss is also the phase where intervention works best, it is the window in which UK guidance focuses attention — and where many women first ask whether HRT is right for them. The key practical point is not a single number but the trajectory: bone you have at menopause is bone worth protecting, because it is harder to rebuild than to preserve. Knowing your starting density gives you something concrete to measure that trajectory against.

Does HRT really protect against osteoporosis and fractures?

Yes — and on the evidence from UK bodies, the protection extends beyond bone density to actual fractures. The NHS lists it plainly: "HRT helps to prevent osteoporosis by increasing your level of oestrogen" (NHS). The Royal Osteoporosis Society goes further, stating that HRT "appears to be as effective as other osteoporosis medicines at lowering the chance of broken bones in postmenopausal women" (Royal Osteoporosis Society).

The trial evidence backs this. Drawing on Women's Health Initiative data, a 2025 systematic review in Cureus reported that HRT was associated with fewer hip fractures (relative risk 0.66) and fewer vertebral (spine) fractures (relative risk 0.64) — meaningful reductions in the fractures that matter most (Cureus, 2025).

Who is HRT recommended for — and who is it not suitable for?

UK guidance points most strongly to younger postmenopausal women and to those whose menopause came early. The 2024 NOGG clinical guideline advises clinicians to "consider offering younger postmenopausal women (age ≤ 60 years) with high fracture risk and low baseline risk for adverse malignant and thromboembolic events HRT as a first-line treatment option" (NOGG 2024 guideline). The Royal Osteoporosis Society echoes this, noting HRT may suit a postmenopausal woman under 60 with a high chance of breaking a bone.

Early and premature menopause raises the stakes. A 23-year UK longitudinal analysis of more than 8,600 women found that those with premature ovarian insufficiency or early menopause had higher odds of osteoporosis (about 37% higher) and of fracture (about 45% higher) than other women — and that starting menopause hormone therapy at or before the study entry age was protective (Human Reproduction, 2024). The NHS reinforces the message: "It's particularly important to take HRT to help prevent osteoporosis if your periods stop before the age of 45."

Diagnostic delay appears to compound the risk. A 2025 study of women with premature ovarian insufficiency and early menopause found 43.1% had osteopenia and 10.3% had osteoporosis at diagnosis, and that diagnosis more than three years after periods stopped was associated with a higher osteoporosis rate than diagnosis within six months — an association on small subgroups, not proof of cause, but a reason to act early (Journal of Clinical Medicine, 2025). HRT is not suitable for everyone — your eligibility depends on your full medical history, including any history of certain cancers or blood clots — which is why this is always a clinician-led decision.

Which type and route of HRT is best for bone health?

For bone, the route matters less than you might expect; for safety, it can matter a lot. A 2022 systematic review in Archives of Gynecology and Obstetrics found that both oral and transdermal (skin patch or gel) HRT had a positive effect on bone density, with no significant difference between the two routes for bone protection (Archives of Gynecology and Obstetrics, 2022).

Where they differ is the risk of venous blood clots. That same review found the clot risk was clearly higher with oral HRT — around four times higher than with transdermal HRT — which is one reason patches and gels are often preferred where clot risk is a concern. The choice of progestogen and whether oestrogen is given alone or combined also plays a role: findings summarised in a 2025 scoping review suggest combined oestrogen-plus-progesterone therapy was associated with greater spine bone density than oestrogen alone (Frontiers in Reproductive Health, 2025). The practical message: there is no single "best" HRT for bones — the right type and route is the one matched to your personal risk profile.

What happens to your bones when you stop HRT?

The protection is not banked — it depends on continuing the oestrogen. The Royal Osteoporosis Society is direct about this: "when you stop taking HRT you will lose its positive effects on your bone strength" (Royal Osteoporosis Society). The 2025 Cureus review reported the same pattern, noting that participants who stopped HRT experienced a loss of bone density.

This is exactly why UK guidance treats stopping as a decision point rather than an endpoint. The 2024 NOGG guideline advises that "when HRT is discontinued, reassess fracture risk and consider an alternative treatment if indicated" (NOGG 2024 guideline). In practice, some women transition to a different osteoporosis medicine once they come off HRT, to keep protecting bone they have already preserved. The common thread is the same one running through this whole article: you cannot manage what you do not measure.

How can you tell whether HRT is actually working for your bones?

You cannot feel bone density — the only way to know whether HRT is doing its job for your skeleton is to measure it and track the change over time. Because the benefit accrues quietly and disappears just as quietly when you stop, an objective baseline and follow-up measurement turn HRT from a hope into a monitored plan.

This is where regular bone screening fits in. A radiation-free REMS bone health assessment measures your bone density without X-ray exposure, which means it can be repeated safely — at the start of treatment and again later — so you can see whether your density is holding steady or shifting. That repeatability is the practical value: it lets you and your clinician check that your chosen route and dose are working for you, and gives you a clear reading to act on if you ever stop. (To be clear, this is the value of having a safe way to re-measure your own bone density over time; it is part of our service offering, not a claim from the studies above.)

You can book a screening for a radiation-free bone health assessment, learn how the REMS technology works, or see where we screen across the UK. If you are weighing HRT, having your own numbers makes that conversation with your GP or menopause specialist far more concrete.

---

This article is part of our menopause and bone health series. If a weight-loss injection is also part of your picture, see our guide on Ozempic and bone loss.